Synapse - Howard Scher

Results (1130)

Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis

Meeting Abstract

Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer

Journal Article

Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
Journal of Immunotherapy and Precision Oncology (2023)

Fulltext@MSK | Save

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study

Meeting Abstract

Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)

Meeting Abstract

Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer

Meeting Abstract

Barnett, E.; Gupta, S.; Erazo, T.; Lam, E.; Carbone, E.; Zanone, M.; Nystrom, L.; Gajar, R. N.; Wenstrup, R.; Scher, H. I.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)

Meeting Abstract

Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Triplet therapy in metastatic hormone-sensitive prostate cancer-calling out the "double Standard"

Editorial

McHugh, D. J.; Scher, H. I.
JAMA Oncology (2023)

Fulltext@MSK | Save

Clinical impact of a rapid genetic testing model for advanced prostate cancer patients

Journal Article

Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
Journal of Urology (2023)

Fulltext@MSK | Save

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Journal Article

Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
European Journal of Cancer (2023)

Fulltext@MSK | Save

A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer

Meeting Abstract

Bryce, A. H.; Karp, D. D.; Tagawa, S. T.; Nordquist, L. T.; Rathkopf, D. E.; Adra, N.; Dorff, T. B.; Baeck, J.; O'Donnell, J. F.; Ames, T. D.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save